SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
SEC Accession No. 0001640334-22-002571
Filing Date
2022-12-06
Accepted
2022-12-06 14:35:46
Documents
7
Period of Report
2022-08-31

Document Format Files

Seq Description Document Type Size
1 FORM 10-K/A lxrp_10ka.htm 10-K/A 57341
2 CONSENT OF DAVIDSON & COMPANY LLP lxrp_ex231.htm EX-23.1 4300
3 CERTIFICATION lxrp_ex311.htm EX-31.1 8838
4 CERTIFICATION lxrp_ex312.htm EX-31.2 11543
5 lxrp_ex231img3.jpg GRAPHIC 7922
6 lxrp_ex231img4.jpg GRAPHIC 8653
7 lxrp_ex231img5.jpg GRAPHIC 5019
  Complete submission text file 0001640334-22-002571.txt   113313
Mailing Address 100 - 740 MCCURDY ROAD KELOWNA A1 V1X 2P7
Business Address 100 - 740 MCCURDY ROAD KELOWNA A1 V1X 2P7 250-765-6424
Lexaria Bioscience Corp. (Filer) CIK: 0001348362 (see all company filings)

IRS No.: 202000871 | State of Incorp.: NV | Fiscal Year End: 0831
Type: 10-K/A | Act: 34 | File No.: 001-39874 | Film No.: 221447381
SIC: 2834 Pharmaceutical Preparations